KR20220007065A - 스핑고신 1 포스페이트 수용체 조절인자 - Google Patents

스핑고신 1 포스페이트 수용체 조절인자 Download PDF

Info

Publication number
KR20220007065A
KR20220007065A KR1020217037136A KR20217037136A KR20220007065A KR 20220007065 A KR20220007065 A KR 20220007065A KR 1020217037136 A KR1020217037136 A KR 1020217037136A KR 20217037136 A KR20217037136 A KR 20217037136A KR 20220007065 A KR20220007065 A KR 20220007065A
Authority
KR
South Korea
Prior art keywords
compound
acid
receptor
pharmaceutically acceptable
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217037136A
Other languages
English (en)
Korean (ko)
Inventor
필립 턴불
에스더 마틴보로
모리스 마시니
Original Assignee
리셉토스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리셉토스 엘엘씨 filed Critical 리셉토스 엘엘씨
Publication of KR20220007065A publication Critical patent/KR20220007065A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217037136A 2019-04-26 2020-03-27 스핑고신 1 포스페이트 수용체 조절인자 Ceased KR20220007065A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839495P 2019-04-26 2019-04-26
US62/839,495 2019-04-26
PCT/US2020/025142 WO2020219207A1 (en) 2019-04-26 2020-03-27 Sphingosine 1 phosphate receptor modulator

Publications (1)

Publication Number Publication Date
KR20220007065A true KR20220007065A (ko) 2022-01-18

Family

ID=72941745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037136A Ceased KR20220007065A (ko) 2019-04-26 2020-03-27 스핑고신 1 포스페이트 수용체 조절인자

Country Status (6)

Country Link
US (1) US20220227722A1 (https=)
EP (1) EP3959204A4 (https=)
JP (1) JP2022529845A (https=)
KR (1) KR20220007065A (https=)
CN (1) CN114008034A (https=)
WO (1) WO2020219207A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021099469A1 (en) * 2019-11-22 2021-05-27 Basf Coatings Gmbh Electrodeposition coating material containing catechol derivatives as anticorrosion agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782991A1 (en) * 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
MX2012005560A (es) * 2009-11-13 2012-10-05 Receptos Inc Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
EP3280703A1 (en) * 2015-04-06 2018-02-14 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
EP3621610A1 (en) * 2017-05-08 2020-03-18 Celgene International II Sàrl Sphingosine 1 phosphate receptor agonists for neuroprotection
CA3061201A1 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios

Also Published As

Publication number Publication date
CN114008034A (zh) 2022-02-01
EP3959204A4 (en) 2022-12-28
EP3959204A1 (en) 2022-03-02
JP2022529845A (ja) 2022-06-24
US20220227722A1 (en) 2022-07-21
WO2020219207A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
EP2985277B1 (en) Method for preparing an atropisomer of a pyrrole derivative
JP6830888B2 (ja) Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法
KR20140147836A (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
JP2019505491A (ja) 自己免疫疾患の処置に有用なビピラゾリル誘導体
RU2720810C2 (ru) Соли производного хиназолина и способ их получения
KR20240004495A (ko) 이소퀴놀론 화합물과 이의 용도
BR112015017963B1 (pt) Composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
WO2012004698A1 (en) Piperidinyl pyrimidine amides as kv7 potassium channel openers
EA036964B1 (ru) Способ получения производных диаминопиримидина и их промежуточные соединения
KR20120044281A (ko) 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
JP2019501927A (ja) Ｂｔｋ阻害剤としてのイソキノロン類
JP2024510935A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
UA127506C2 (uk) ПОХІДНІ ПІРОЛО[1,2-b]ПІРИДАЗИНУ
WO2019008034A1 (en) CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE
KR20240125004A (ko) Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법
KR20220007065A (ko) 스핑고신 1 포스페이트 수용체 조절인자
KR20220129495A (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형
CN109553604B (zh) 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
US12428386B2 (en) Sphingosine 1 phosphate receptor modulators
EP4126827B1 (en) Sphingosine 1 phosphate receptor modulators
EP4582086A2 (en) Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same
JP5077232B2 (ja) ベンゾオキサジアゾール誘導体の結晶
RU2812575C2 (ru) Ингибитор jak и способ его получения
EP4398989A1 (en) Thienopyrrole compounds
WO2015080665A1 (en) Chalcone-urea derivatives as insulin sensors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250310

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250516

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D